Yourgene Health (LON: YGEN) said it has been awarded a Framework Agreement under Public Health England’s (PHE) National Microbiology Framework for Lot 1 (Diagnostic Goods and Services) of the four-lot tender for its Clarigene SARS-CoV-2 assay and Manchester-based COVID testing service.
The PHE’s National Microbiology Framework is appointing suppliers to framework agreements for four lots. Lot 1 is the first to be announced and covers the supply of in-vitro diagnostic medical devices and associated services, including YGEN’s Clarigene SARS-CoV-2 PCR assay.
The Framework Agreement is for an initial two years with options to extend by up to a further two years.
As mentioned in the Genedrive article, the framework contract is not exclusive to them or a guarantee of orders, but it allows participating authorities to issue call-off orders for products in the future.
“ Yourgene considers that the successful framework award, for which there was a competitive tender process, lends significant credibility to the Clarigene® product and to the Company’s COVID testing services. More broadly, we expect the award to support business development outside the scope of this agreement with a growing network of commercial partners, addressing privately funded testing in healthcare and workplace settings,” said Lyn Rees, CEO of YGEN.
Yourgene’s share price is currently trading 3.5% above Friday’s close at 15.52p.
Should you invest in Yourgene Health shares?
Yourgene Health shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Yourgene Health shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies